Kirk Tanner

3.7k total citations · 2 hit papers
30 papers, 3.0k citations indexed

About

Kirk Tanner is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Kirk Tanner has authored 30 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 10 papers in Oncology and 6 papers in Genetics. Recurrent topics in Kirk Tanner's work include Glioma Diagnosis and Treatment (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Genomics and Chromatin Dynamics (5 papers). Kirk Tanner is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Histone Deacetylase Inhibitors Research (5 papers) and Genomics and Chromatin Dynamics (5 papers). Kirk Tanner collaborates with scholars based in United States, Switzerland and Australia. Kirk Tanner's co-authors include John M. Denu, C. David Allis, Rolf Sternglanz, Joseph W. Landry, Wang L. Cheung, Paolo Sassone‐Corsi, Peter Cheung, Michael Langer, Young‐Joo Kim and Jack Kyte and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Kirk Tanner

30 papers receiving 2.9k citations

Hit Papers

Specific and Reversible Inactivation of Protein Tyrosine ... 1998 2026 2007 2016 1998 2000 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kirk Tanner United States 16 2.2k 390 386 347 293 30 3.0k
Guri Tzivion United States 26 3.4k 1.5× 606 1.6× 297 0.8× 240 0.7× 250 0.9× 35 4.1k
Tobias B. Dansen Netherlands 31 3.1k 1.4× 437 1.1× 290 0.8× 303 0.9× 569 1.9× 50 4.1k
Arthur S. Polans United States 28 2.3k 1.0× 216 0.6× 206 0.5× 345 1.0× 178 0.6× 48 3.1k
Phuongmai Nguyen United States 23 2.0k 0.9× 430 1.1× 255 0.7× 666 1.9× 376 1.3× 31 2.9k
Curtis L. Ashendel United States 25 2.1k 1.0× 327 0.8× 333 0.9× 96 0.3× 204 0.7× 52 3.0k
Tomoaki Kahyo Japan 22 1.4k 0.6× 567 1.5× 230 0.6× 124 0.4× 141 0.5× 90 2.2k
Zhongtao Zhang United States 26 1.4k 0.6× 426 1.1× 289 0.7× 110 0.3× 135 0.5× 36 2.1k
Mandy Kwong United States 14 1.1k 0.5× 180 0.5× 365 0.9× 94 0.3× 173 0.6× 21 1.7k
Kheem S. Bisht United States 23 1.4k 0.6× 264 0.7× 111 0.3× 594 1.7× 333 1.1× 33 2.4k
Doris Germain United States 32 2.2k 1.0× 780 2.0× 167 0.4× 185 0.5× 272 0.9× 73 3.1k

Countries citing papers authored by Kirk Tanner

Since Specialization
Citations

This map shows the geographic impact of Kirk Tanner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk Tanner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk Tanner more than expected).

Fields of papers citing papers by Kirk Tanner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk Tanner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk Tanner. The network helps show where Kirk Tanner may publish in the future.

Co-authorship network of co-authors of Kirk Tanner

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk Tanner. A scholar is included among the top collaborators of Kirk Tanner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk Tanner. Kirk Tanner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rahman, Rifaquat, Diana D. Shi, Zachary J. Reitman, et al.. (2024). DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro-Oncology. 26(8). 1367–1387. 7 indexed citations
2.
Brown, Christine E., Samantha Bucktrout, Lisa H. Butterfield, et al.. (2022). The future of cancer immunotherapy for brain tumors: a collaborative workshop. Journal of Translational Medicine. 20(1). 236–236. 9 indexed citations
3.
Cloughesy, Timothy F., Brian M. Alexander, Donald A. Berry, et al.. (2022). GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.. Journal of Clinical Oncology. 40(16_suppl). TPS2078–TPS2078. 4 indexed citations
4.
Siah, Kien Wei, et al.. (2021). Accelerating glioblastoma therapeutics via venture philanthropy. Drug Discovery Today. 26(7). 1744–1749. 11 indexed citations
5.
Rahman, Rifaquat, Steffen Ventz, Irmarie Reyes‐Rivera, et al.. (2021). Leveraging external data in the design and analysis of clinical trials in neuro-oncology. The Lancet Oncology. 22(10). e456–e465. 52 indexed citations
6.
Qin, Yuan, Barbara R. Tschida, Ben Staal, et al.. (2020). Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice. Neuro-Oncology Advances. 2(1). vdaa067–vdaa067. 8 indexed citations
7.
Newsome, David, Daigo Takemoto, Shawn Hillier, et al.. (2017). Abstract P5-06-05: Preclinical characterization of VX-984, a selective DNA-dependent protein kinase (DNA-PK) inhibitor in combination with doxorubicin in breast and ovarian cancers. Cancer Research. 77(4_Supplement). P5–6. 5 indexed citations
8.
Hillier, Shawn, David Newsome, Daigo Takemoto, et al.. (2016). Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy. Annals of Oncology. 27. vi122–vi122. 4 indexed citations
9.
Johnson, Jennifer, Maria Libera Ascierto, Sandeep Mittal, et al.. (2015). Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. Journal of Translational Medicine. 13(1). 306–306. 18 indexed citations
10.
Haar, Ernst ter, et al.. (2010). 3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3β. Bioorganic & Medicinal Chemistry Letters. 20(5). 1661–1664. 56 indexed citations
11.
Brown, Kate, G Walker, David Grant, et al.. (2004). Predicting outcome in ex-premature infants supported with extracorporeal membrane oxygenation for acute hypoxic respiratory failure. Archives of Disease in Childhood Fetal & Neonatal. 89(5). F423–F427. 11 indexed citations
12.
Denu, John M. & Kirk Tanner. (2002). [29] Redox regulation of protein tyrosine phosphatases by hydrogen peroxide: Detecting sulfenic acid intermediates and examining reversible inactivation. Methods in enzymology on CD-ROM/Methods in enzymology. 348. 297–305. 46 indexed citations
13.
Cheung, Peter, Kirk Tanner, Wang L. Cheung, et al.. (2000). Synergistic Coupling of Histone H3 Phosphorylation and Acetylation in Response to Epidermal Growth Factor Stimulation. Molecular Cell. 5(6). 905–915. 643 indexed citations breakdown →
14.
Kim, Young‐Joo, Kirk Tanner, & John M. Denu. (2000). A Continuous, Nonradioactive Assay for Histone Acetyltransferases. Analytical Biochemistry. 280(2). 308–314. 85 indexed citations
15.
Tanner, Kirk, Michael Langer, & John M. Denu. (2000). Kinetic Mechanism of Human Histone Acetyltransferase P/CAF. Biochemistry. 39(50). 15652–15652. 13 indexed citations
16.
Tanner, Kirk, Michael Langer, Young‐Joo Kim, & John M. Denu. (2000). Kinetic Mechanism of the Histone Acetyltransferase GCN5 from Yeast. Journal of Biological Chemistry. 275(29). 22048–22055. 126 indexed citations
17.
Tanner, Kirk, Raymond C. Trievel, Min‐Hao Kuo, et al.. (1999). Catalytic Mechanism and Function of Invariant Glutamic Acid 173 from the Histone Acetyltransferase GCN5 Transcriptional Coactivator. Journal of Biological Chemistry. 274(26). 18157–18160. 193 indexed citations
18.
Tanner, Kirk, et al.. (1999). Extracellular Regulated Kinases (ERK) 1 and ERK2 Are Authentic Substrates for the Dual-specificity Protein-tyrosine Phosphatase VHR. Journal of Biological Chemistry. 274(19). 13271–13280. 139 indexed citations
19.
Denu, John M. & Kirk Tanner. (1998). Specific and Reversible Inactivation of Protein Tyrosine Phosphatases by Hydrogen Peroxide:  Evidence for a Sulfenic Acid Intermediate and Implications for Redox Regulation. Biochemistry. 37(16). 5633–5642. 775 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026